



**Eurofins brings together the expertise of MWG Operon and Medigenomix under a new global brand, *Eurofins Genomics*, to provide seamless best-in-class genomics services worldwide**

**2 April 2014**

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces that it is combining its competencies to provide the most complete suite of genomics services in the market. Eurofins MWG Operon, a pioneer and key provider of genomic services, and Eurofins Medigenomix, the Group's competence center for applied solutions in DNA & RNA analysis, are being brought together under the new global brand name **Eurofins Genomics**.

The new brand represents the genomics division of the Eurofins Scientific Group, and consolidates its market presence as a provider of full genomic services in various market segments. **Eurofins Genomics** operates leading R&D and production sites in the USA (Huntsville, AL and Louisville, KY), Germany (Ebersberg), India (Bangalore) and Japan (Tokyo).

**Eurofins Genomics** services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Together with the international laboratory network of the Eurofins Group, **Eurofins Genomics** has an outstanding team of experts utilizing a broad range of state-of-the-art technologies to provide the highest quality of service in DNA & RNA oligonucleotides, custom DNA and next generation sequencing, gene synthesis and molecular biology, as well as genotyping and gene expression.

Comment from Bruno Poddevin, Senior Vice President Eurofins Genomics: *"After years of continuous growth within the Eurofins Scientific network, I am extremely happy to align our traditional brands, "MWG", "Operon" and "Medigenomix", under a single brand which is synonymous with our commitment to be first-in-class provider of genomic services. This underlines our goal to strengthen our global position as the leading supplier of applied genomics solutions in the future"*.

**For more information, please visit [www.eurofinsgenomics.com](http://www.eurofinsgenomics.com) or contact:**

**Eurofins Genomics Europe**

Carola Grimmingier  
Email:  
carolagrimmingier@eurofins.com  
Phone: +49 8092 8289-921

**Eurofins Genomics Americas**

James Come  
Email:  
jamescome@eurofins.com  
Phone: +1 256 704 8200

**Eurofins Genomics Japan**

Takahiro Obana  
Email:  
takahiroobana@eurofins.com  
Phone: +81 3 5492 7001

**Eurofins Genomics India**

Sanjeev Kamte  
Email:  
sanjeevkamte@eurofins.com  
Phone: +91 80 3070 6666

**Notes for the editor:**

**About Eurofins Genomics**

Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its customer convenience, fast delivery and high quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit our website at [eurofinsgenomics.com](http://eurofinsgenomics.com).

### **Eurofins – a global leader in bio-analysis**

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services.

With about 15,000 staff in more than 190 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

### **Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.